Anti-Human CD19 – DyLight® 755

Purified Recombinant Human CD19 (>98%)

This DyLight^® 755 conjugate is formulated in 0.01 M phosphate buffered saline (PBS) pH 7.4, 150 mM NaCl, 1% BSA and 0.09% sodium azide as a preservative.

This DyLight^® 755 conjugate is stable when stored at 2-8°C. Do not freeze.

Next Day 2-8°C

Clone SJ25-C1 recognizes an epitope on human CD19.

CD19 is a 95 kD transmembrane glycoprotein and member of the Ig superfamily. The antigen serves as an adaptor protein; drawing cytoplasmic signaling proteins to the membrane. It works via the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Because of its presence on all B cells, CD19 is a biomarker for B lymphocyte development, lymphoma diagnosis and can be utilized as a target for the immunotherapy of lymphoproliferative disorders. Emerging studies indicate that CD19 plays an active role in fueling the growth of these cancers, most notably by stabilizing the concentrations of the MYC oncoprotein, making CD19 an attractive therapeutic target with respect to its downstream signaling.

CD19 is expressed in the majority of Pro-B cells to mature B cells (during development) and follicular dendritic cells. Plasma cells do not express CD19.

Forms complex with CD21 (CR2) and CD81 (TAPA-1), BCR coreceptor

1. Leukocyte Typing III (1987) Oxford University Press: Code No.: 073 2. Leukocyte Typing II (1986) Oxford University Press